Clinical Trials Logo
  1. Home
  2. Chronic Bronchitis
  3. NCT00360464
  4. Details
NCT00360464 Clinical Trial

A Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases

Acute Bronchitis Clinical Trial

Official title:
A Multicenter, Non-Randomized, Open Label Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases In Japan Adults

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00360464
Other study ID # A0661175
Secondary ID
Status Completed
Phase Phase 3
First received August 3, 2006
Last updated April 20, 2011
Start date October 2006
Est. completion date June 2007

Study information
Verified date April 2011
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority Japan: Ministry of Health, Labor and Welfare
Study type Interventional

Clinical Trial Summary

To evaluate the clinical efficacy and safety in patients with Acute Bronchitis or Secondary Infection of Chronic Respiratory Diseases receiving a dose of 2 g of azithromycin in the SR formulation.

Recruitment information / eligibility
Status Completed
Enrollment 64
Est. completion date June 2007
Est. primary completion date June 2007
Accepts healthy volunteers No
Gender Both
Age group 16 Years to 80 Years
Eligibility Inclusion Criteria:

- Patients who were diagnosed as mild or moderate in severity by the classification of infection of the Japanese Society of Chemotherapy guidelines for the evaluation methods of new antibacterial drug (established in 1997).

Exclusion Criteria:

- Severe underlying disease; patients in which drug clinical evaluation is difficult because of confounding diseases.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Azithromycin SR

Locations
Country Name City State
Japan Pfizer Investigational Site Akiruno Tokyo
Japan Pfizer Investigational Site Chofu Tokyo
Japan Pfizer Investigational Site Chofu Tokyo
Japan Pfizer Investigational Site Hitachinaka Ibaraki
Japan Pfizer Investigational Site Kami-gun Miyagi
Japan Pfizer Investigational Site Kasama Ibaraki
Japan Pfizer Investigational Site Katano Osaka
Japan Pfizer Investigational Site Kodaira Tokyo
Japan Pfizer Investigational Site Moriya Ibaraki
Japan Pfizer Investigational Site Nakano Tokyo
Japan Pfizer Investigational Site Setagaya Tokyo
Japan Pfizer Investigational Site Shigesato-cho, Nagasaki Nagasaki
Japan Pfizer Investigational Site Shinagawa Tokyo
Japan Pfizer Investigational Site Shindoori, Niigata-shi Niigata
Japan Pfizer Investigational Site Toride Ibaraki
Japan Pfizer Investigational Site Tsuchiura Ibaraki
Japan Pfizer Investigational Site Yokohama Kanagawa
Japan Pfizer Investigational Site Yokosuka Kangawa
Japan Pfizer Investigational Site Yonezawa Yamagata

Sponsors (1)
Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

Japan, 

Outcome
Type Measure Description Time frame Safety issue
Primary The primary endpoint is investigator's clinical efficacy at Day 8.
Secondary Endpoints of efficacy are as follows: Investigator's clinical efficacy (at Day 15 and 29), and the tendency toward clinical improvement (at Day 4); Bacteriological efficacy (at Day 4, 8, 15 and 29); Safety Endpoints: Adverse events and safety lab data.
See also
  Status Clinical Trial Phase
Completed NCT03711292 - Using Behavioral Science to Reduce Inappropriate Antibiotic Use in Acute Care Settings N/A
Not yet recruiting NCT03517215 - The Development and Testing of a Scaling Strategy for a Community-Based Primary Care Antimicrobial Stewardship Program N/A
Completed NCT01420445 - Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis Phase 2
Completed NCT05344638 - A Clinical Trial to Evaluate the Safety and Efficacy of "AG1904" in Acute Bronchitis Phase 3
Completed NCT06457269 - Evaluating the Potential of Large Language Models for Respiratory Disease Consultations N/A
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting NCT03827590 - Clinical Trials to Assess the Efficacy and Safety of HLIM Phase 3
Completed NCT02792946 - Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis Phase 3
Completed NCT01875757 - Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life Phase 3
Recruiting NCT04252963 - Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase) Phase 4
Recruiting NCT06411925 - The Efficacy and Safety of Atock Dry Syrup With Acute Bronchitis Patients Phase 4
Completed NCT01416480 - Clinical Trial to Evaluate the Safety and Efficacy of "Theobromine Capsule" as an Antitussive in Acute Cougher Phase 3
Enrolling by invitation NCT05916768 - Management of Acute Bronchitis With Pelargonium Sidoides Extract N/A
Completed NCT03309800 - A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Placebo in Acute Bronchitis Patients Phase 2
Completed NCT02250027 - A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on) Phase 2
Not yet recruiting NCT03310385 - Efficacy and Safety of GHX02 in the Treatment of Acute Bronchitis Phase 2
Completed NCT03654196 - A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab in Acute Bronchitis Patients Phase 3
Completed NCT03011515 - Evaluating a Host-response Based Diagnostic for Distinguishing Between Bacterial and Viral Etiology in Patients With Lower Respiratory Tract Infection (LRTI)
Completed NCT02045394 - Epidemiology and Diagnosis of Haemoptysis: a Multicenter Study N/A
Completed NCT01800747 - Clinical Trial for the Assessment of Delayed Antibiotic Treatment in Pediatric (DAP-Pediatrics) Phase 4

External Links